Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888750 | 1.00 | HPGD (0.45) | HPGDGAANOS2ALDH1A1HTT | |
| SCHEMBL888758 | 1.00 | HPGD (0.45) | HPGDGAANOS2ALDH1A1HTT | |
| SCHEMBL22047383 | 0.94 | HPGD (0.42) | HPGDGAANOS2ALDH1A1HTT | |
| SCHEMBL19913373 | 0.94 | HPGD (0.42) | HPGDGAANOS2ALDH1A1HTT | |
| SCHEMBL22047386 | 0.83 | HPGD (0.46) | HPGDGAANOS2ALDH1A1HTT | |
| Thiophene SCHEMBL27508217 | 0.81 | HPGD (0.40) | HPGDGAAALDH1A1HTTTSHR | |
| SCHEMBL15377304 | 0.80 | HPGD (0.42) | HPGDGAANOS2ALDH1A1HTT | |
| SCHEMBL6077735 | 0.80 | NOS2 (0.42) | HPGDGAANOS2ALDH1A1HTT | |
| SCHEMBL28145524 | 0.80 | TDP1 (0.44) | HPGDGAANOS2ALDH1A1HTT | |
| SCHEMBL27813128 | 0.77 | GAA (0.30) | HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | MAKRIYANNIS ALEXANDROS (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | MAKRIYANNIS ALEXANDROS (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | MAKRIYANNIS ALEXANDROS (US) | 2021-09-30 | — | — | US | disclosed |
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11034645-B2 | Treprostinil derivatives and compositions and uses thereof | Corsair Pharma, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-20200071257-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | Corsair Pharma, Inc. (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2020023355-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | LOMMEN GUY R E | 2007-07-19 | — | — | US | disclosed |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | LOMMEN GUY R E | 2007-07-19 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | HPGD 347/4885GAA 559/4885NOS2 2049/4885 |
| US-20200071257-A1 | TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF | PTGIS, PTGIR, PDE3A | HPGD 25/4885GAA 1269/4885NOS2 92/4885 |
| US-11746113-B2 | Labelled cannabinergic ligands and related analogs | CNR1, CNR2, CHRND | HPGD 360/4885GAA 4679/4885NOS2 977/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | HPGD 1775/4885GAA 223/4885NOS2 3457/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | HPGD 171/4885GAA 4099/4885NOS2 1285/4885 |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | HPGD 347/4885GAA 559/4885NOS2 2049/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | HPGD 954/4885GAA 4009/4885NOS2 2610/4885 |
| US-11802105-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | HPGD 25/4885GAA 1269/4885NOS2 92/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | HPGD 1775/4885GAA 223/4885NOS2 3457/4885 |
| US-11034645-B2 | Treprostinil derivatives and compositions and uses thereof | PTGIS, PTGIR, PDE3A | HPGD 25/4885GAA 1269/4885NOS2 92/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | HPGD 2788/4885GAA 2347/4885NOS2 1363/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | HPGD 2017/4885GAA 1486/4885NOS2 1368/4885 |
| US-20210300937-A1 | Novel Labelled Cannabinergic Ligands and Related Analogs | CNR1, CNR2, CHRND | HPGD 431/4885GAA 4681/4885NOS2 772/4885 |
| US-20070167456-A1 | Mercaptoimidazoles as ccr2 receptor antagonists | CCR2, CCR1, CCR5 | HPGD 1963/4885GAA 4880/4885NOS2 1594/4885 |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | HPGD 1775/4885GAA 223/4885NOS2 3457/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | HPGD 2453/4885GAA 3444/4885NOS2 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.